| Literature DB >> 23170138 |
Xian-Lu Zhuo1, Jun-Jun Ling, Hou-Yu Zhao, Yan Zhou, Yu-Feng Song, Ying-Hui Tan.
Abstract
Evidence implicates cyclin D1 (CCND1) G870A polymorphisms as risk factors for various cancers. An increasing number of investigations have been conducted on the association of CCND1 G870A polymorphisms with susceptibility to oral carcinoma, and have yielded inconclusive results. The aim of the present study was to derive a more precise estimation of the correlation. Meta-analyses examining the association between CCND1 G870A polymorphisms and oral carcinoma were performed. Separate analyses on ethnicity, smoking status and control sources were also implemented. Eligible studies were identified prior to February 2012. From the overall data from 1,128 cases and 1,276 controls, no associations of CCND1 G870A polymorphisms with oral carcinoma were observed [AA vs. GG: odds ratio (OR)=1.06; 95% confidence interval (CI), 0.62-1.82; dominant model: OR=1.04; 95% CI, 0.76-1.43; recessive model: OR=1.06; 95% CI, 0.70-1.59]. In the subgroup analysis by ethnicity, smoking status and control sources, no significant associations of CCND1 G870A polymorphisms and oral cancer were observed for the three genetic models. Collectively, the data failed to suggest CCND1 G870A polymorphism as a low-penetrant risk factor for developing oral carcinoma. Additional studies with large sample sizes concerning different ethnicities in different areas are required.Entities:
Year: 2012 PMID: 23170138 PMCID: PMC3501437 DOI: 10.3892/etm.2012.648
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Characteristics of the studies included in the meta-analysis.
| First author | Year of publication | No. of cases (male/female) | No. of controls (male/female) | Type of controls | Age range (mean), years
| Country | |
|---|---|---|---|---|---|---|---|
| Cases | Controls | ||||||
| Matthias ( | 1998 | 38 (25/13) | 191 (149/42) | 191 non-cancerous controls (hospital-based) | NA (59.29) | NA (NA) | Germany |
| Wong ( | 2003 | 70 (65/5) | 93 (74/19) | 93 controls (population-based) | 31–82 (53.3) | 22–75 (49.4) | China |
| Holley ( | 2005 | 174 (135/39) | 155 (125/30) | 155 non-cancerous controls (hospital-based) | NA (55.6) | NA (59.9) | Germany |
| Sathyan ( | 2006 | 176 (119/57) | 142 (98/44) | 142 non-cancerous controls (age-, gender-matched; hospital-based) | 36–85 (59) | 35–80 (58) | India |
| Gomes ( | 2008 | 80 (60/20) | 80 (59/21) | 80 healthy individuals (age-, gender, tobacco usage-matched; population-based) | 39–82 (57.5) | 39–85 (53.5) | Brazil |
| Tsai ( | 2011 | 620 (586/34) | 620 (586/34) | 620 non-cancerous controls (age-, gender-, habit-matched; hospital-based) | NA (52.4) | NA (51.3) | China |
NA, not available.
Distribution of the CCND1 genotype among oral cancer cases and controls included in the meta-analysis.
| First author | Genotyping method | Cases
| Controls
| HWE (control)
| |||||
|---|---|---|---|---|---|---|---|---|---|
| AA | AG | GG | AA | AG | GG | Chi-square | P-value | ||
| Matthias | PCR-RFLP | 11 | 20 | 7 | 35 | 101 | 55 | 0.918 | >0.05 |
| Wong | PCR-SSCP | 19 | 36 | 15 | 27 | 49 | 17 | 0.406 | >0.05 |
| Holley | PCR-RFLP | 14 | 94 | 66 | 28 | 87 | 40 | 2.593 | >0.05 |
| Sathyan | PCR-SSCP | 39 | 71 | 36 | 36 | 61 | 40 | 1.620 | >0.05 |
| Gomes | PCR-RFLP | 25 | 30 | 25 | 23 | 29 | 28 | 5.926 | <0.05 |
| Tsai | PCR-RFLP | 213 | 323 | 84 | 155 | 365 | 100 | 21.625 | <0.05 |
HWE, Hardy-Weinberg equilibrium.
Main results of the pooled data in the meta-analysis.
| Variable | No. (cases/controls) | AA vs. GG
| (AA+AG) vs. GG
| AA vs. (AG+GG)
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P-value | P-value (Q-test) | OR (95% CI) | P-value | P-value (Q-test) | OR (95% CI) | P-value | P-value (Q-test) | ||
| Total | 1128/1276 | 1.06 (0.62–1.82) | 0.83 | 0.002 | 1.04 (0.76–1.43) | 0.80 | 0.08 | 1.06 (0.70–1.59) | 0.80 | 0.006 |
| Ethnicity | ||||||||||
| Caucasian | 212/346 | 0.84 (0.11–6.54) | 0.87 | 0.001 | 0.95 (0.31–2.90) | 0.93 | 0.02 | 0.84 (0.19–3.73) | 0.82 | 0.004 |
| Asian | 836/850 | 1.37 (0.97–1.95) | 0.08 | 0.3 | 1.18 (0.92–1.53) | 0.20 | 0.62 | 1.25 (0.88–1.79) | 0.22 | 0.16 |
| Mixed | 80/80 | 1.22 (0.56–2.66) | 0.62 | NA | 1.18 (0.61–2.29) | 0.61 | NA | 1.13 (0.57–2.22) | 0.73 | NA |
| Smoking status | ||||||||||
| Ever smoking | 602/588 | 0.55 (0.04–7.12) | 0.65 | 0.000 | 0.83 (0.32–2.20) | 0.71 | 0.002 | 0.62 (0.07–5.38) | 0.66 | 0.000 |
| Never smoking | 188/342 | 1.16 (0.65–2.08) | 0.61 | 0.71 | 1.01 (0.61–1.67) | 0.96 | 0.75 | 1.22 (0.81–1.85) | 0.34 | 0.82 |
| Source of control | ||||||||||
| Hospital-based | 978/1103 | 1.09 (0.50–2.38) | 0.83 | 0.001 | 1.06 (0.68–1.66) | 0.78 | 0.03 | 1.06 (0.59–1.91) | 0.85 | 0.002 |
| Population-based | 150/173 | 1.02 (0.56–1.84) | 0.96 | 0.49 | 1.02 (0.61–1.68) | 0.95 | 0.48 | 1.02 (0.63–1.65) | 0.95 | 0.67 |
NA, not applicable.
Figure 1Meta-analysis for the association of oral cancer risk with CCND1 polymorphisms (AA vs. GG).
Figure 3Meta-analysis for the association of oral cancer risk with CCND1 polymorphisms (AA vs. AG+GG).
Figure 4Funnel plot and Egger’s linear regression test (AA+AG vs. GG).